Discover Thomson Reuters
Biogen’s market value rose $11 bln on news its new treatment for the disease appeared effective. Robert Cyran explains why this rise is rather cautious, and how the drug might exceed Wall Street’s assumptions.
01:51
01:58
01:29
02:07
01:53
02:09
01:49
01:05
00:37
01:10
01:13
04:47
01:46
01:37
01:36
01:42
01:57
01:00
02:39